BEND, Ore.--(BUSINESS WIRE)--
Independent testing laboratory in final phase
to perform state compliance testing
EVIO Inc. (âEVIOâ or the âCompanyâ),
(EVIO), a leading provider of cannabis
testing and research for the regulated cannabis industry in North
America announced today that it received a provisional license from
Massachusetts Cannabis Control Commission (CCC) to operate as an
independent testing laboratory. The license moves the organization
into the final phase of being cleared to commence testing cannabis
under the Commonwealthâs Adult Use of Marijuana Program. EVIO Labs
in Framingham will be one of only four Massachusetts laboratories
approved to perform mandated testing to measure product potency and
to verify that cannabis is clean from contaminants including
pesticides, heavy metals, including lead and mercury, and microbes,
including e. coli and salmonella.
âWe are excited to offer full service testing for
the stateâs exploding adult-use market. The first two recreational
cannabis dispensaries opened on November 20, 2018 and according to
the CCC, sales exceeded $2 million in the first five days.
Additional dispensaries are awaiting final license approval to
enter this $1.2B cannabis market. We have already established
relationships with a majority of the growers and producers across
the Commonwealth and we look forward to serving them,â said Lori
Glauser, COO of EVIO. âAs more consumers try cannabis including CBD
products, it is vitally important that the product is safe, and the
product labels are accurate.â
The provisional license permits EVIO Labs to
complete the relocation to its new Framingham facility, reoptimize
the equipment to support EVIOâs ISO accredited methods and complete
preparations for final inspection. We are forecasting this process
will be complete within the next 30 to 45 days.
About EVIO Inc.
EVIO Inc. is a leading provider of cannabis
testing and scientific research for the regulated cannabis
industry. The Companyâs EVIO Labs division operates coast-to-coast
providing state-mandated ancillary services to ensure the safety
and quality of the nation's cannabis supply. The Companyâs EVIO
Biosciences Division is dedicated to the scientific, medical, and
psychosocial exploration of clinical cannabis, cannabinoids, and
the endocannabinoid system.
For more information, visit www.eviolabs.com.
Safe Harbor Statement
Any statements in this press release that are not
statements of historical fact maybe considered to be
forward-looking statements. Statements may contain certain
forward-looking statements pertaining to future anticipated or
projected plans, performance and developments, as well as other
statements relating to future operations and results. Words such as
"may," "will," "expect," "believe," "anticipate," "estimate,"
"intends," "goal," "objective," "seek," "attempt," or variations of
these or similar words, identify forward-looking statements. These
forward-looking statements by their nature are estimates of future
results only and involve substantial risks and uncertainties,
including but not limited to risks associated with the uncertainty
of future financial results, additional financing requirements,
development of new products, our ability to complete our product
testing and launch our product commercially, the acceptance of our
product in the marketplace, the uncertainty of the laws and
regulations relating to cannabis, the impact of competitive
products or pricing, technological changes, the effect of economic
conditions and other uncertainties detailed from time to time in
our reports filed with the Securities and Exchange Commission,
available at www.sec.gov or www.eviolabs.com.
View source version on